Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash & Equivalents: 2014-2025

Historic Cash & Equivalents for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $100.4 million.

  • Viking Therapeutics' Cash & Equivalents rose 99.37% to $100.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.4 million, marking a year-over-year increase of 99.37%. This contributed to the annual value of $26.7 million for FY2024, which is 51.95% down from last year.
  • Per Viking Therapeutics' latest filing, its Cash & Equivalents stood at $100.4 million for Q3 2025, which was up 196.27% from $33.9 million recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Cash & Equivalents peaked at $195.6 million during Q1 2024, and registered a low of $8.8 million during Q2 2021.
  • Its 3-year average for Cash & Equivalents is $60.8 million, with a median of $43.9 million in 2024.
  • In the last 5 years, Viking Therapeutics' Cash & Equivalents soared by 1,629.43% in 2022 and then tumbled by 89.72% in 2023.
  • Over the past 5 years, Viking Therapeutics' Cash & Equivalents (Quarterly) stood at $26.4 million in 2021, then spiked by 38.91% to $36.6 million in 2022, then spiked by 51.55% to $55.5 million in 2023, then plummeted by 51.95% to $26.7 million in 2024, then soared by 99.37% to $100.4 million in 2025.
  • Its last three reported values are $100.4 million in Q3 2025, $33.9 million for Q2 2025, and $37.9 million during Q1 2025.